Thursday, October 15, 2026
ExploreSearch
Via News
Via News Knowledge File

NVIDIA Corporation

organization80% conf.·synced Oct 15, 2026

Technology company specializing in semiconductors and AI chips, IPO in 1999, Taiwan semiconductor dependency

60
sourced metrics
5478
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
221.30USD
Oct 14, 2026reference only
Price 52 Week Low
165.17USD
Oct 14, 2026reference only
Stock Return Ytd
17.2%
Oct 14, 2026reference only
Market Cap
5355460000000USD
Oct 14, 2026reference only
Price 52 Week High
239.24USD
Oct 14, 2026reference only
Shares Outstanding
24200000000.0shares
May 15, 2026reference only
Gross Profit
61157000000.0USD
Apr 26, 2026reference only
Stockholders Equity
195474000000.0USD
Apr 26, 2026reference only
Net Income
58321000000.0USD
Apr 26, 2026reference only
Total Liabilities
64000000000.0USD
Apr 26, 2026reference only
Operating Income
53536000000.0USD
Apr 26, 2026reference only
Rd Expense
6321000000.0USD
Apr 26, 2026reference only
Total Assets
259474000000.0USD
Apr 26, 2026reference only
Cost Of Revenue
20458000000.0USD
Apr 26, 2026reference only
Operating Cash Flow
50344000000.0USD
Apr 26, 2026reference only
Revenue
81615000000.0USD
Apr 26, 2026reference only
Cash
13237000000.0USD
Apr 26, 2026reference only
Eps
2.39USD_per_share
Apr 26, 2026reference only

Stated objectives

Regain billions of dollars in lost business through China market

source
target: billions stated

Share 15% or more of revenue from China sales with US government

source
target: 15 stated

Commission over 1 million square feet for manufacturing Blackwell chips in Arizona and AI supercomputers in Texas

source
target: 1 million square feet stated

Ramp up mass production of AI supercomputers in Texas by September 2026

source
by 2026-09-01 00:00:00stated

Q4 FY2026 revenue target

source
target: $65.0 billion, plus or minus 2% by 2026-01-25 00:00:00stated

Q4 FY2026 GAAP gross margin target

source
target: 74.8%, plus or minus 50 basis points by 2026-01-25 00:00:00stated

Q4 FY2026 non-GAAP gross margin target

source
target: 75.0%, plus or minus 50 basis points by 2026-01-25 00:00:00stated

Start shipping H200 chips to China

source
by 2026-02-01 00:00:00stated

Deliver up to 10x reduction in inference token cost compared to Blackwell platform

source
target: 10x stated

Reduce number of GPUs needed to train MoE models by 4x compared to Blackwell

source
target: 4x reduction stated

Relationship graph · 5478 connections

Developed by
1328
Supplies to
909
Competes with
729
Covered by
505
Customer of
424
Employs
320
Invested in
224
Partners with
176

Via News coverage

Micron's Spending Has Roughly Doubled as AI Strains the Chip Supply, and Rivals Are Racing for Alternatives
October 8, 2026
Everyone Plans to Deploy AI Agents. Few Can Show Them Their Own Data.
October 7, 2026
Every Company Plans to Use AI Agents. The Hard Part Is Whether Their Data Is Ready
October 4, 2026
Everyone Plans to Use AI Agents. The Hard Part Is the Data Behind Them, and the Strongest Numbers Are in Chips
October 2, 2026
AI Agents Are Moving Into Banks and Insurers, but Their Access to Trustworthy Data Is Not Keeping Pace
September 29, 2026
Enterprise AI Agents Are Racing Ahead of the Data and Trust Needed to Ground Them
September 29, 2026
Adobe's Miss, Alphabet's Squeeze, and an Executive Exodus: The Market Stops Rewarding the AI Story and Starts Asking for Results
September 16, 2026
Nvidia's $950 Billion Week and a Memory Chip Rally Wall Street May Be Underrating
September 13, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com